India Central Lab Market Size and Trends for 2026

The India central lab market size is calculated at USD 166.38 million in 2025 and is expected to be worth USD 542.15 million by 2035, expanding at a CAGR of 12.41% from 2026 to 2035, as a result of rising investment in R&D and rising demand for clinical trials.

Key Takeaways

• Global central lab sector pushed the market to USD 7.17 billion by 2026.
• North America held a major revenue share of 43.65% of the central lab market in 2025.
• Asia-Pacific held 21.98% of the market share in 2025 and is expected to witness the fastest growth with a CAGR of 11.22% during the predicted timeframe.
• By service type, the safety testing segment held the largest revenue share of 29.75% of the market in 2025.
• By service type, the genomic & molecular testing segment held 19.56% market share in 2025 and is expected to grow with the highest CAGR of 10.77% in the market during the studied years.
• By therapeutic area, the oncology segment held the largest market share of 32.87% in 2025.
• By therapeutic area, the rare diseases & genetic disorders segment held 4.93% market share in 2025, and is estimated to be the fastest-growing with 13.10% CAGR during the forecast period.
• By clinical trial phase, the phase III segment led with 50.32% market share in 2025.
• By clinical trial phase, the phase IV held 15.01% market share and is expected to grow at the fastest CAGR Of 10.02% during the forecast period.
• By modality, the biologics segment contributed the biggest revenue share of 36.16% of the central lab market in 2025.
• By modality, the advanced therapies segment held 16.87% of the market in 2025 and is expected to witness the fastest growth with 13.22% CAGR in the market over the forecast period.
• By end-user, the pharmaceutical & biotechnology companies segment contributed the biggest revenue share of 61.17% of the market in 2025.
• By end-user, the contract research organizations (CROs) segment held 17.21% share in 2025 and is expected to witness the fastest growth of 10.52% in the market over the forecast period.

The Central Lab Supports Clinical Trials and Helps in Clinical Testing

A central laboratory is a medical lab that provides services to numerous sites or institutions and this concept also covers off-site laboratories that provide support services to clinical laboratories housed in healthcare facilities, it exclusively serves one hospital or institution. The corporate-type labs and national reference laboratory systems are two more words that are used to describe central lab services. Central lab lowers costs for the pharmaceutical and biotechnology industries and also guarantees that results are delivered more quickly and accurately.

The pharmaceutical and biopharmaceutical firms have completely outsourced central labs. During the evaluation period, the worldwide central lab market will continue to have strong potential due to rising pharmaceutical and biotechnology company activity as well as the rising need for novel medications and vaccines. Moreover, from covid 19 pandemic crisis the demand for central laboratories is continuously driving an increase in research & development and conducting clinical trials.

Pharmaceutical Giants are Accelerating the Growth in Central Lab Market

A central lab, also known as a central laboratory, is a specialized facility for conducting various laboratory tests and analyses. These labs are typically used in clinical trials, where they are responsible for performing a range of analyses on samples of blood, urine, tissue, and other materials collected from study participants. The goal of central labs is to provide consistent and reliable data across multiple study sites, which can then be used to evaluate the safety and effectiveness of new drugs, medical devices, or other healthcare interventions.

Central labs typically use advanced laboratory equipment and technologies, such as automated sample processing systems, high-throughput screening systems, and sophisticated analytical instruments. They are staffed by trained technicians and scientists who are responsible for conducting the tests and interpreting the results.

In addition to clinical trials, central labs may also be used for other types of laboratory testing, such as diagnostic testing for infectious diseases or genetic testing for inherited conditions. These labs may be operated by private companies, academic institutions, or government agencies, and they may be located in a variety of settings, including hospitals, research centers, and specialized laboratory facilities.

Top Companies in the Central Lab Market

• ACM Global Laboratories
• CIRION BioPharma Research
• Eurofins Scientific
• ICON plc
• Intermountain Health
• IQVIA
• LabConnect
• Labcorp
• Medpace
• Reprocell
• SGS S.A.
• Thermo Fisher Scientific

Segments Covered in the Report

By Service Type

• Safety Testing
  
  • Hematology
  • Clinical Chemistry (Metabolic Panels, Urinalysis)
  • Coagulation & Liver Function Testing
• Specialty Testing & Biomarkers
  
  • Biomarker Services
  • Flow Cytometry
  • Multiplex Assays
• Genomic & Molecular Testing
  
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence in Situ Hybridization (FISH)
  • Gene Expression Profiling
• Pathology & Histology Services
  
  • Anatomic Pathology
  • Cytopathology
  • Immunohistochemistry (IHC)
• Microbiology & Virology
  
  • Pathogen Surveillance
  • Viral Load Monitoring
• Clinical Supply Chain & Biorepository
  
  • Specimen Management
  • Kit Preparation
  • Logistics & Cold Chain Management
  • Cryopreservation
    

By Therapeutic Area

• Oncology
  • Immuno-oncology
  • Hematological Malignancies
• Infectious Diseases
  
  • Virological Research (HIV, COVID-19, Hepatitis)
  • Bacterial & Fungal Infections
  • Tropical & Emerging Diseases
• Cardiovascular & Metabolic Diseases (CVMD)
  
  • Diabetes
  • Obesity
  • Heart Failure
• Neurology & Central Nervous System (CNS)
  • Alzheimer’s & Dementia
  • Multiple Sclerosis
  • Rare Neurological Disorders
• Immunology & Autoimmune Diseases
  
  • Rheumatoid Arthritis
  • Psoriasis & Inflammatory Bowel Disease (IBD)
• Rare Diseases & Genetic Disorders

By Clinical Trial Phase

• Phase I & II (Early Phase)
• Phase III (Late Phase)
• Phase IV (Post-Marketing Surveillance)

By Modality

• Small Molecules
• Biologics (Large Molecules)
  
  • Monoclonal Antibodies
  • Recombinant Proteins
• Advanced Therapies (ATMP)
  
  • Cell Therapy
  • Gene Therapy
• Vaccines

By End-User

• Pharmaceutical & Biotechnology Companies
  
  • Large Cap Pharma
  • Emerging Biotech
• Contract Research Organizations (CROs)
• Academic & Government Research Institutes
• Clinical Diagnostic Laboratories